Lataa...
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial
In the Study of Tamoxifen and Raloxifene (STAR) trial, postmenopausal women at increased risk of breast cancer received either oral tamoxifen (20 mg/day) or raloxifene (60 mg/day) over 5 years. There were an equal number of cases of invasive breast cancer in women assigned to tamoxifen and raloxifen...
Tallennettuna:
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2009
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2785111/ https://ncbi.nlm.nih.gov/pubmed/19105706 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/14737140.9.1.51 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|